Episode
From Australia to China: CTI's APAC Growth Journey
- Podcast
- Moving Medicine Forward
- Published
- Jul 15, 2026
- Duration seconds
- 805
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/moving-medicine-forward-6832193/episodes/from-australia-to-china-cti-s-apac-growth-journey/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/moving-medicine-forward-6832193/from-australia-to-china-cti-s-apac-growth-journey.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Asia Pacific has become one of the fastest-growing regions in clinical research, offering sponsors new opportunities to advance clinical development in an increasingly complex global environment. In this episode, Pavels Anetko, Director of Clinical Operations and Clinical Project Management at CTI, shares insights from across the region, including Australia's strengths in early phase studies and CTI's recent expansion into China and Japan. 01:24 Pavels’ background, career journey, and leadership role overseeing CTI's project management teams across Asia Pacific. 02:13 Why APAC is one of the fastest-growing regions for clinical development and the increasing influence of China. 02:41 CTI's growth strategy in Australia and the region's advantages for early-phase research, including the CTN regulatory pathway and R&D tax incentives. 04:06 The rise of healthy volunteer and Phase I studies in Australia. 04:27 Building CTI's presence in China and Japan and navigating more complex regulatory environments. 05:05 Staying aligned with regional regulatory requirements while maintaining global clinical trial standards. 05:40 How CTI helps sponsors select the right countries, sites, and patient populations across APAC. 06:20 Why local infrastructure, language expertise, and in-country teams are critical to trial success. 07:09 Challenges sponsors face when entering new APAC markets and how local support reduces risk. 07:36 The strategic value of including Japan and China in global studies, including access to patients and regulatory considerations. 08:58 How APAC can accelerate development timelines and strengthen regulatory submissions. 09:38 Key operational considerations for global studies, including logistics, specimen handling, and country-specific requirements. 10:08 Emer…